On April Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, reported that will host a virtual R&D Day on April 26, 2022 starting at 8:30 a.m. ET (Press release, Cyteir Therapeutics, APR 18, 2022, View Source [SID1234612413]). Cyteir’s management will discuss the research done to identify the molecular target of CYT-0851 and review the ongoing clinical plan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio webcast can be accessed via the Investor Relations section of the Company’s website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir’s website for 30 days.